Advertisement
YOU ARE HERE: LAT HomeCollections

California | IN BRIEF / California

Maxim Begins New Drug Study

January 18, 2002|Bloomberg News

Maxim Pharmaceuticals Inc. is trying again to win regulatory approval of a medicine previously rejected by the Food and Drug Administration by starting a new study of patients with advanced skin cancer.

The San Diego drug maker began a 224-patient trial designed to show that patients survive longer with its experimental compound Ceplene. The trial compares patients getting Ceplene and the approved treatment interleukin-2 with those getting IL-2 alone, Maxim said.

Maxim shares rose 23 cents to close at $6.35 on Nasdaq.

Advertisement
Los Angeles Times Articles
|
|
|